Progressive pulmonary fibrosis (PPF) is an increasingly recognised condition, defined in 2022 to address the progression of ...

A persistent, often progressive, lung disease, COPD results from chronic inflammation that leads to structural changes ...

As our digital focus continues, Daniel Ghinn explores the growing anticipation around Boehringer Ingelheim’s launch of Syrum – the first pharmaceutical social game – ahead of its beta launch ...

AllianceQUANTRO Therapeutics and IMP enter into research collaboration to accelerate transcriptomic drug discovery 24.10.2024 / 09:30 CET/CESTThe issuer is solely responsible for the content of this ...

Founded in 1885 and family-owned ever since, Boehringer Ingelheim takes a long-term, sustainable perspective. More than 53,000 employees serve over 130 markets in the two business units Human Pharma ...

Dr Arshad Khanani previews the 2024 American Academy of Ophthalmology Annual Meeting, particularly the retina subspecialty day focusing on wet age-related macular degeneration (AMD), with highlights ...

Global Pleural Diseases Therapeutics MarketThe global market for pleural diseases therapeutics is projected to experience ...

Co., Ltd. (“Nxera” or “the Company”; TSE 4565) – formerly known as Sosei Group or Sosei Heptares – is pleased to announce ...

One of the primary factors fueling the growth of the DOACs market is the rapid uptake and expected utilization within the ...

FRANKFURT: The CEO of pharmaceuticals giant Roche, opens new tab said authorities should block the takeover of contract drug ...

The CEO of pharmaceuticals giant Roche has urged authorities to block the takeover of contract drug manufacturer Catalent by ...